Alfred Knable, MD
Dermatology · New Albany, INNPI 1174538912
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $180,775 of the $202,691 with a category attached, or 89.2%. AbbVie accounts for 77.4% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2019 at $93,964 and has fallen 77.5% since, to $21,135 in 2025. Among dermatology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 742 payments — averaging $273.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$157K
- Pfizer$34K
- Journey Medical Corporation$5K
- Novartis$1K
- Johnson & Johnson$791
- Lilly USA, LLC$623
- plus $4K from 31 others
What the payments were for
- Consulting fees$1,1251%
- Speaking & faculty fees$180,77589%
- Travel & lodging$6,3403%
- Food & beverage$14,1557%
- Education$2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 326 | $156,866 |
| Pfizer | 42 | $34,130 |
| Journey Medical Corporation | 13 | $4,680 |
| Novartis | 93 | $1,497 |
| Johnson & Johnson | 32 | $791 |
| Lilly USA, LLC | 34 | $623 |
| UCB, Inc. | 21 | $614 |
| Regeneron Healthcare Solutions, Inc. | 27 | $565 |
| E.r. Squibb & Sons, L.L.C. | 23 | $447 |
| Galderma Laboratories, L.p. | 26 | $371 |
| Boehringer Ingelheim | 14 | $332 |
| Amgen | 12 | $245 |
| Incyte Corporation | 7 | $244 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $185 |
| Sun Pharmaceutical Industries Inc. | 9 | $181 |
| Sanofi | 8 | $155 |
| Bristol Myers Squibb | 11 | $130 |
| EPI Health, LLC | 5 | $103 |
| Dermavant Sciences, Inc. | 4 | $64 |
| Prugen, Inc. Pharmaceuticals | 4 | $49 |
| Revance Therapeutics, Inc. | 1 | $47 |
| Genentech USA, Inc. | 3 | $43 |
| Botanix SB Inc | 2 | $36 |
| Mayne Pharma Commercial LLC | 2 | $35 |
| Dermira, Inc. | 1 | $33 |
| Arcutis Biotherapeutics, Inc. | 2 | $32 |
| Blueprint Medicines Corporation | 1 | $22 |
| Organon | 1 | $22 |
| LEO Pharma Inc. | 1 | $21 |
| VYNE Pharmaceuticals Inc. | 1 | $19 |
| Almirall LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Biofrontera Inc. | 1 | $16 |
| Convatec Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Taro Pharmaceuticals USA, Inc. | 1 | $12 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$202,691 in reported general payments places this provider in the 95th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $314,279 |
| Humira(Cf) PenAdalimumab | 32 | $219,832 |
| Dupixent PenDupilumab | 36 | $136,896 |
| Taltz AutoinjectorIxekizumab | 12 | $83,413 |
| Betamethasone Dipropionate | 60 | $2,358 |
| Clobetasol Propionate | 55 | $2,346 |
| Metronidazole | 33 | $1,998 |
| Triamcinolone Acetonide | 213 | $1,827 |
| Doxycycline Hyclate | 55 | $1,752 |
| Fluorouracil | 21 | $1,716 |
| Clindamycin Phosphate | 68 | $1,530 |
| Acitretin | 12 | $1,313 |
| CiclopiroxCiclopirox Olamine | 51 | $1,264 |
| Hydroxychloroquine Sulfate | 20 | $1,131 |
| Pentoxifylline | 32 | $919 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New Albany
- Ashley ReaderNew Albany$15K
- Scott GuenthnerPlainfield$1.6M
- David RosmarinIndianapolis$1.1M
- Christopher ObeimeIndianapolis$907K
- Scott FretzinIndianapolis$794K
- Priya YoungIndianapolis$492K
- Jeffrey SassmannshausenFort Wayne$489K
- Nikolajs PerdueIndianapolis$302K
- Michael SheehanColumbus$297K
- Megan LandisCorydon$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.